Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1986 Sep;204(3):223–235. doi: 10.1097/00000658-198609000-00002

Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection.

M T Lotze, J A Carrasquillo, J N Weinstein, G J Bryant, P Perentesis, J C Reynolds, L A Matis, R R Eger, A M Keenan, I Hellström, et al.
PMCID: PMC1251268  PMID: 3753057

Abstract

Fab fragments of monoclonal antibodies (MoAb) to melanoma, radiolabeled with 131I, were evaluated as diagnostic reagents to determine their ability to localize systemic--MoAb injected intravenously (IV)--or nodal metastatic disease--injected subcutaneously (SQ) at a site proximal to draining lymph nodes. Sixty-one scans were performed (40 IV, 21 SQ) in 59 patients who had injections of 0.2-50 mg of 131I coupled (0.2-12 mCi) antibody. These included 48.7, which identifies a high molecular weight antigen (HMW), or 96.5, which identifies a transferrin like molecule, p97. 125I coupled nonspecific Fab 1.4, reacting with murine leukemia virus, or the whole antibody BL3, reactive with a human B cell idiotypic determinant, was generally used in tandem with the patients injected SQ as a nonspecific control. All patients had immunohistochemical studies performed on biopsied lesions and demonstrated binding to the antibodies injected. Of the IV patients, 22/38 (58%) had (+) scans, 13 at SQ or nodal sites, four at visceral sites, and five at visceral and SQ sites. Patients with clinical stage II disease had SQ injection of MoAb, including 11 additional patients injected with the whole antibody 9.2.27 (anti-HMW) labeled with 111In (6 patients) or 131I (5 patients). Nodal dissection was performed 2-4 days later. All 111In coupled antibodies demonstrated excellent nodal delineation without specific identification of tumor deposits. Of the 21 patients injected SQ with MoAb, 17 had confirmed tumor in nodes. Of patients injected with Fab fragments, 4/8 (50%) had specific uptake of MoAb, although only two were successfully imaged. Increased uptake of antimelanoma antibodies was observed in some patients in lymph nodes not containing tumor and was possibly related to antigen shedding. Clearance of labeled antibody from the injection site occurred with a half life of 16-50 hours. Toxicity was limited to local discomfort at the site of SQ injection. Melanoma metastases can be identified with IV or SQ injection or radiolabeled antibodies. These reagents may be useful in the diagnosis or therapy of human melanoma. Further evaluation will be required before they could be considered clinically useful.

Full text

PDF
223

Images in this article

230FIG. 3.
on p.230
230FIG. 4.
on p.230
232FIG. 7.
on p.232
232FIG. 8.
on p.232
233FIG. 10.
on p.233
233FIG. 11.
on p.233

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balch C. M., Soong S. J., Milton G. W., Shaw H. M., McGovern V. J., Murad T. M., McCarthy W. H., Maddox W. A. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982 Dec;196(6):677–684. doi: 10.1097/00000658-198212001-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown J. P., Woodbury R. G., Hart C. E., Hellström I., Hellström K. E. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A. 1981 Jan;78(1):539–543. doi: 10.1073/pnas.78.1.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fee H. J., Robinson D. S., Sample W. F., Graham L. S., Holmes E. C., Morton D. L. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study. Surgery. 1978 Nov;84(5):626–632. [PubMed] [Google Scholar]
  4. Ferens J. M., Krohn K. A., Beaumier P. L., Brown J. P., Hellström I., Hellström K. E., Carrasquillo J. A., Larson S. M. High-level iodination of monoclonal antibody fragments for radiotherapy. J Nucl Med. 1984 Mar;25(3):367–370. [PubMed] [Google Scholar]
  5. Goodman G. E., Beaumier P., Hellström I., Fernyhough B., Hellström K. E. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol. 1985 Mar;3(3):340–352. doi: 10.1200/JCO.1985.3.3.340. [DOI] [PubMed] [Google Scholar]
  6. Hellström I., Brankovan V., Hellström K. E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1499–1502. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hellström I., Garrigues H. J., Cabasco L., Mosely G. H., Brown J. P., Hellström K. E. Studies of a high molecular weight human melanoma-associated antigen. J Immunol. 1983 Mar;130(3):1467–1472. [PubMed] [Google Scholar]
  8. Houghton A. N., Mintzer D., Cordon-Cardo C., Welt S., Fliegel B., Vadhan S., Carswell E., Melamed M. R., Oettgen H. F., Old L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242–1246. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kim E. E., Corgan R. L., Casper S., Primus F. J., Spremulli E., Estes N., Goldenberg D. M. Axillary lymphoscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer. J Nucl Med. 1979 Dec;20(12):1243–1250. [PubMed] [Google Scholar]
  10. Krejcarek G. E., Tucker K. L. Covalent attachment of chelating groups to macromolecules. Biochem Biophys Res Commun. 1977 Jul 25;77(2):581–585. doi: 10.1016/s0006-291x(77)80018-1. [DOI] [PubMed] [Google Scholar]
  11. Krizan Z., Murray J. L., Hersh E. M., Rosenblum M. G., Glenn H. J., Gschwind C. R., Carlo D. J. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants. Cancer Res. 1985 Oct;45(10):4904–4909. [PubMed] [Google Scholar]
  12. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  13. Larson S. M., Brown J. P., Wright P. W., Carrasquillo J. A., Hellström I., Hellström K. E. Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med. 1983 Feb;24(2):123–129. [PubMed] [Google Scholar]
  14. Larson S. M., Carrasquillo J. A., Krohn K. A., Brown J. P., McGuffin R. W., Ferens J. M., Graham M. M., Hill L. D., Beaumier P. L., Hellström K. E. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983 Dec;72(6):2101–2114. doi: 10.1172/JCI111175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McCarthy W. H., Shaw H. M., Milton G. W. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet. 1985 Dec;161(6):575–580. [PubMed] [Google Scholar]
  16. Morgan A. C., Jr, Galloway D. R., Reisfeld R. A. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma. 1981;1(1):27–36. doi: 10.1089/hyb.1.1981.1.27. [DOI] [PubMed] [Google Scholar]
  17. Murray J. L., Rosenblum M. G., Sobol R. E., Bartholomew R. M., Plager C. E., Haynie T. P., Jahns M. F., Glenn H. J., Lamki L., Benjamin R. S. Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. Cancer Res. 1985 May;45(5):2376–2381. [PubMed] [Google Scholar]
  18. Order S. E., Bloomer W. D., Jones A. G., Kaplan W. D., Davis M. A., Adelstein S. J., Hellman S. Radionuclide immunoglobulin lymphangiography: a case report. Cancer. 1975 Jun;35(6):1487–1492. doi: 10.1002/1097-0142(197506)35:6<1487::aid-cncr2820350602>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  19. Real F. X., Houghton A. N., Albino A. P., Cordon-Cardo C., Melamed M. R., Oettgen H. F., Old L. J. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 1985 Sep;45(9):4401–4411. [PubMed] [Google Scholar]
  20. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  21. Rosenblum M. G., Murray J. L., Haynie T. P., Glenn H. J., Jahns M. F., Benjamin R. S., Frincke J. M., Carlo D. J., Hersh E. M. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res. 1985 May;45(5):2382–2386. [PubMed] [Google Scholar]
  22. Silverberg E. Cancer statistics. 1986. CA Cancer J Clin. 1986 Jan-Feb;36(1):9–25. doi: 10.3322/canjclin.36.1.9. [DOI] [PubMed] [Google Scholar]
  23. Sim F. H., Taylor W. F., Ivins J. C., Pritchard D. J., Soule E. H. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978 Mar;41(3):948–956. doi: 10.1002/1097-0142(197803)41:3<948::aid-cncr2820410324>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  24. Steller M. A., Parker R. J., Covell D. G., Holton O. D., 3rd, Keenan A. M., Sieber S. M., Weinstein J. N. Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence. Cancer Res. 1986 Apr;46(4 Pt 1):1830–1834. [PubMed] [Google Scholar]
  25. Veronesi U., Adamus J., Bandiera D. C., Brennhovd I. O., Caceres E., Cascinelli N., Claudio F., Ikonopisov R. L., Javorskj V. V., Kirov S. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977 Sep 22;297(12):627–630. doi: 10.1056/NEJM197709222971202. [DOI] [PubMed] [Google Scholar]
  26. Wanebo H. J., Harpole D., Teates C. D. Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. Cancer. 1985 Mar 15;55(6):1403–1413. doi: 10.1002/1097-0142(19850315)55:6<1403::aid-cncr2820550640>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  27. Weinstein J. N., Parker R. J., Holton O. D., 3rd, Keenan A. M., Covell D. G., Black C. D., Sieber S. M. Lymphatic delivery of monoclonal antibodies: potential for detection and treatment of lymph node metastases. Cancer Invest. 1985;3(1):85–95. doi: 10.3109/07357908509040610. [DOI] [PubMed] [Google Scholar]
  28. Weinstein J. N., Parker R. J., Keenan A. M., Dower S. K., Morse H. C., 3rd, Sieber S. M. Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science. 1982 Dec 24;218(4579):1334–1337. doi: 10.1126/science.7146917. [DOI] [PubMed] [Google Scholar]
  29. Weinstein J. N., Steller M. A., Keenan A. M., Covell D. G., Key M. E., Sieber S. M., Oldham R. K., Hwang K. M., Parker R. J. Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor. Science. 1983 Oct 28;222(4622):423–426. doi: 10.1126/science.6623082. [DOI] [PubMed] [Google Scholar]
  30. Ziegler-Heitbrock H. W., Munker R., Johnson J., Petersmann I., Schmoeckel C., Riethmüller G. In vitro differentiation of human melanoma cells analyzed with monoclonal antibodies. Cancer Res. 1985 Mar;45(3):1344–1350. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES